Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant
Phase 2
Terminated
- Conditions
- Hodgkin's LymphomaMultiple MyelomaNon-Hodgkin's Lymphoma
- Interventions
- Dietary Supplement: Nestle Impact Advanced Recovery
- Registration Number
- NCT01699581
- Lead Sponsor
- Greg Monohan
- Brief Summary
Nestle Impact has shown efficacy in multiple surgical trials in relation to improving hospital length of stay and infection rate. 1 dose of Nestle Impact Advanced Recovery will be taken orally three times a day beginning on the morning following stem cell transplant and will continue until the day of hospital discharge.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
- Patients receiving an autologous stem cell transplant using the preparative regimens of BEAM (Carmustine, Etoposide, Cytarabine, Melphalan), Melphalan 140mg/m2, or Melphalan 200mg/m2
- Any prior diet or supplement will be allowed.
- Age >18 years.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nestle Impact including fish oil.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Nestle Impact Advanced Recovery Nestle Impact Advanced Recovery Nestle Impact Advanced Recovery 1 dose of Nestle Impact Advanced Recovery orally three times a day
- Primary Outcome Measures
Name Time Method Hospital length of stay Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge Days to engraftment Particpants will be followed for 14 days, the average length of time from stem cell infusion until dischcarge
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Kentucky, Markey Cancer Center
🇺🇸Lexington, Kentucky, United States